Furthermore, we found no differences in gene expression of markers of TIL activation (CD69) [52, 53], exhaustion (LAG‐3), or tumor immune evasion (PD‐L1); however, our strategy could not provide a definitive assessment of the proportion of the activation/exhaustion status within the TIL subset. The gene discussed is STMN1; the disease is neoplasm.